Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HEMOGLOBIN-BASED BLOOD SUBSTITUTES: FURTHER PRECLINICALS

Executive Summary

HEMOGLOBIN-BASED BLOOD SUBSTITUTES: FURTHER PRECLINICALS and Phase I safety studies should be conducted before efficacy trials proceed, FDA's Blood Products Advisory Committee concluded in a March 15 draft "consensus statement." The draft document, which summarizes conclusions from the committee's March 14 closed session with companies at work on hemoglobin-derived red cell substitutes, recommends a number of specific preclinical and clinical studies to address unexplained toxicities seen in previous safety trials. The advisory committee's suggestions include in vitro product characterization tests, animal studies "in several species," including primates, and safety studies in healthy human volunteers. The committee suggested that the initial human safety studies begin at low doses (i.e., 250 mg/kg), with careful monitoring of circulatory and immune parameters, including complement/kinin/coagulation cascades, histamine release, and levels of thromboxane metabolites and leukotrienes. After establishing safety at low doses, the document proposes that studies at higher doses should continue in normal volunteers before firms begin efficacy testing. The document emphasizes that while the panel members remain "concerned about the intensity and severity of unexplained reactions in human recipients," they continue to support development of hemoglobin-based oxygen carriers. Toxicities from hemoglobin-derived blood substitutes pose a risk to the kidneys and liver, heart, lungs and vascular system, immune system, central nervous system, and reticuloendothelial system, according to the committee's statements. The committee also found that the source of observed toxic effects has not been determined conclusively, listing hemoglobin itself, its breakdown products such as heme, hemichrome, free iron and hemoglobin dimers, and manufacturing contaminants as potential sources of adverse effects. * Northfield Labs, of Evanston, Illinois, is among the companies that have been developing hemoglobin-derived red cell substitutes. The company said it is unclear how the committee's recommendations would affect the firm's Phase I testing program for its polymerized hemoglobin-product. According to FDA, no firms have progressed further than initial Phase I studies for such products.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS017117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel